Savara Inc. (NASDAQ:SVRA) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Brian Himes on Jun 10th, 2026

Savara Inc. (NASDAQ:SVRA – Get Free Report) has received an average rating of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $10.1429.

A number of equities research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating on shares of Savara in a report on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. William Blair set a $10.00 price objective on shares of Savara in a research note on Monday, March 16th. Oppenheimer started coverage on Savara in a report on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective for the company. Finally, Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th.

View Our Latest Stock Report on Savara

Hedge Funds Weigh In On Savara

A number of large investors have recently modified their holdings of SVRA. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Savara by 48.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after purchasing an additional 3,205 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in Savara during the 1st quarter worth approximately $57,000. Russell Investments Group Ltd. increased its position in Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after purchasing an additional 9,463 shares in the last quarter. Xponance LLC purchased a new position in Savara in the fourth quarter valued at approximately $66,000. Finally, CIBC Bancorp USA Inc. purchased a new position in Savara in the third quarter valued at approximately $44,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Stock Performance

NASDAQ SVRA opened at $4.93 on Wednesday. The business’s 50-day moving average price is $5.30 and its 200 day moving average price is $5.59. Savara has a twelve month low of $1.98 and a twelve month high of $7.01. The company has a market capitalization of $1.01 billion, a PE ratio of -8.80 and a beta of 0.26. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.17.

Savara (NASDAQ:SVRA – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, research analysts predict that Savara will post -0.57 earnings per share for the current year.

Savara Company Profile

(Get Free Report)

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.